Delivery of high-quality biomarker assays

Disease Markers

Volumn 18, Issue 2, 2002, Pages 47-56

  Swanson, Brian N ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Assay; Bioanalytical; Biomarker; CLIA; Drug development; GLP; Pharmaceutical; Quality; Regulations; Review; Validation

Indexed keywords

BIOLOGICAL FACTOR; BIOLOGICAL MARKER;

ACCURACY; AGE; ANTIBODY SPECIFICITY; ARTICLE; ASSAY; BIOLOGICAL RHYTHM; BODY POSTURE; CLINICAL MEDICINE; DEVELOPMENT; DIET; DISEASE MARKER; DOCUMENTATION; DOSE RESPONSE; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENDER; GENOMICS; HEALTH CARE; HUMAN; MEASUREMENT; PRIORITY JOURNAL; RESEARCH; SENSITIVITY AND SPECIFICITY; STORAGE; TECHNIQUE;

EID: 0036402924     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/212987     Document Type: Article

References (50)

1. N. Arvidson, B. Gudbjornsson, L. Elfman, A.-C. Rydén, T.H. Tötterman and R. Hällgren, Circadian rhythm of serum interleukin-6 in rheumatoid arthritis, Ann Rheum Dis 53 (1994), 521-524.
2. Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications, A Multidisciplinary, International Conference Sponsored by NIH and FDA, Natcher Conference Center, National Institutes of Health, Bethesda, MD, April 15-16, 1999.
3. Code of Federal Regulations, Title 21, Volume 1 [Revised as of April 1, 2001], US Government Printing Office via GPO Access, 21CFR58, Good Laboratory Practice for Nonclinical Laboratory Studies.
4. Code of Federal Regulations, Title 42, Volume 3 [Revised as of October 1, 2001], US Government Printing Office via GPO Access, 42CFR493, Clinical Laboratory Improvement Amendments.
5. L. Bubendorf, High-throughput microarray technologies: from genomics to clinics, Eur Urol 40 (2001), 231-238.
6. L.M. Burrell, J. Palmer, J.A. Charlton, T. Thomas and P.H. Baylis, A new radioimmunoassay for human alpha atrial natriuretic peptide and its physiological validation, J Immunoassay 11 (1990), 159-175.
7. D. Burnett and C. Blair, Standards for the medical laboratory - harmonization and subsidiarity, Clin Chim Acta 309 (2001), 137-145.
8. R. Causon, Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion, J Chromatogr B Biomed Sci Appl 689 (1997), 175-180.
9. A. Cruvchik, G. Subramanian, S. Bruder and J.C. Venter, Sequence analysis of the human genome: implications for the understanding of nervous system function and disease, Arch Neurol 58 (2001), 1772-1778.
10. I.B. Dugue, E. Leppanen and R. Grasbeck, Preanalytical factors and the measurement of cytokines in human subjects, Int J Clin Lab Res 26 (1996), 99-105.
11. J.W. Findlay, W.C. Smith, J.W. Lee, G.D. Nordblom, I. Das, B.S. DeSilva, M.N. Khan and R.R. Bowsher, Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective, J Pharm Biomed Anal 21 (2000), 1249-1273.
12. C.G. Fraser, Biological Variation: From Principles to Practice, AACC Press, Washington, DC, 2001, pp. 151.
13. B.J. Gertz, J.D. Clemens, S.D. Holland and S. Greenspan, Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment, Calc Tiss Int 63 (1998), 102-106.
14. D.J. Goldie, Accreditation of external quality assessment schemes in the United Kingdom, Clin Chim Acta 309 (2001), 179-181.
15. J.J. Going and B.A. Gusterson, Molecular pathology and future developments, Eur J Cancer 35 (1999), 1895-1904.
16. Guidance for Industry, Bioanalytical Method Validation, US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, May 2001, pp. 22.
17. W.B. Hamlin, Requirements for accreditation by the College of American Pathologists Laboratory Accreditation Program, Arch Pathol Lab Med 123 (1999), 465-467.
18. C. Hartmann, D.L. Massart and R.D. McDowall, An analysis of the Washington Conference Report on bioanalytical method validation, J Pharm Biomed Anal 11 (1994), 1337-1343.
19. C. Hartmann, J. Smeyers-Verbeke, D.L. Massart and R.D. McDowall, Validation of bioanalytical chromatographic methods, J Pharm Biomed Anal 17 (1998), 193-218.
20. P. Hess and D. Cooper, Impact of pharmacogenomics on the clinical laboratory, Mol Diagn 4 (1999), 289-298.
21. E. Hofmann, What can medicine learn from the human DNA sequence? Biochem 66 (2001), 1144-1152.
22. W. Huisman, European Communities Confederation of Clinical Chemistry Working Group on Accreditation: past, present and future, Clin Chim Acta 309 (2001), 111-114.
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Text on validation of analytical procedures, 1994.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of analytical procedures: methodology, 1996.
25. K.M. Irjala and P.E. Gronroos, Preanalytical and analytical factors affecting laboratory results, Ann Med 30 (1998), 267-272.
26. D. Kenny, ISO and CEN documents on quality in medical laboratories, Clin Chim Acta 309 (2001), 121-125.
27. J. Kristiansen, Description of a generally applicable model for the evaluation of uncertainty of measurement in clinical chemistry, Clin Chem Lab Med 10 (2001), 920-931.
28. U. Landegren, Consulting the source code: prospects for gene-based medical diagnostics, J Intern Med 248 (2000), 271-276.
29. Z. Laszlo, A. Rossler and H.G. Hinghofer-Szalkay, Cardiovascular and humoral readjustment after different levels of head-up tilt in humans, Aviat Space Environ Med 72 (2001), 193-201.
30. J.C. Libeer, Role of external quality assurance schemes in assessing and improving quality in medical laboratories, Clin Chim Acta 309 (2001), 173-177.
31. C. Kluft, A.f. Jie, D.C. Rijkin and J.H. Verheijen, Daytime fluctuations in blood tissue-type plasminogen activator (t-PA) and its fast acting inhibitor (PAI-1), Thromb Haemost 59 (1988), 329-332.
32. D.H. Manicourt, P. Poilvache, A. Nzeusseu, A. van Egeren, J.P. Devogelaer, M.E. Lenz and E.J.-M.A. Thonar, Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1, change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest, Arthritis Rheum 42 (1999), 1861-1869.
33. T.A. Manolio, G.L. Burke, P.J. Savage, D.R. Jacobs, Jr, S. Sidney, L.E. Wagenknecht, R.M. Allman and R.P. Tracy, Sex and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study, Clin Chem 38 (1992), 1853-1859.
34. S. Narayanan, The preanalytic phase. An important component of laboratory medicine, Am J Clin Pathol 113 (2000), 429-452, Comment in: Am J Clin Pathol. 114 (2000), 820-821.
35. M.A. Owen, H.G. Vall, A.A. Hurley and S.B. Wormsley, Validation and quality control of immunophenotyping in clinical flow cytometry, J Immunol Meth 243 (2000), 33-50.
36. F. Podo, O. Henriksen, W.M. Bovee, M.O. Leach, D. Leibfritz and J.D. de Certaines, Absolute metabolite quantification by in vivo NMR spectroscopy: I. Introduction, objectives and activities of a concerted action in biomedical research, Magn Reson Imaging 16 (1998), 1085-1092.
37. C. Ricos, V. Alvarez, F. Cava, J.V. Garcia-Lario, A. Hernandez, C.V. Jimenez, J. Minchinela, C. Perich and M. Simon, Current databases on biological variation: pros, cons and progress, Scand J Clin Lab Invest 59 (1999), 491-500.
38. K.W. Ryder and M.R. Glick, Erroneous laboratory results from hemolyzed, icteric, and lipemic specimens, Clin Chem 39 (1993), 175-176.
39. C. Sander, Genomic medicine and the future of health care, Science 287 (2000), 1977-1988.
40. L. Sciacovelli, S. Secchiero, L. Zardo and M. Plebani, External Quality Assessment Schemes: need for recognised requirements, Clin Chim Acta 309 (2001), 183-199.
41. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. Pittman and S. Spector, Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. Conference Report, Europ J. Drug Metabolism and Pharmacokinetics 16 (1991), 249-255.
42. V.P. Shah, K.K. Midha, J.W.A. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilveray, G. McKay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli, C.T. Viswanathan and A. Yacobi, Bioanalytical method validation, a revisit with a decade of progress, Pharm Res 17 (2000), 1551-1557.
43. M.M. Shi, Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies, Clin Chem 47 (2001), 164-172.
44. S. Slagter and J.G. Loeber, Accreditation of medical laboratories in The Netherlands, Clin Chim Acta 309 (2001), 155-161.
45. G. Sterner, M. Wroblewski and U. Rosen, Postprandial increase in serum creatinine in renal transplant recipients, Transpl Int 5 (1992), 115-117.
46. L.M. Szymanski and R.R. Pate, Effects of exercise intensity, duration, and time of day on fibrinolytic activity in physically active men, Med Sci Sports Exerc 26 (1994), 1102-1108.
47. N.W. Tietz, D.F. Shuey and D.R. Wekstein, Laboratory values in fit aging individuals - sexagenarians through centenarians, Clin Chem 38 (1992), 1167-1185.
48. N. Wedemeyer and T. Potter, Flow cytometry: an "old" tool for novel applications in medical genetics, Clin Genet 60 (2001), 1-8.
49. J.O. Westgard, Basic Method Validation, AACC Press, Washington, DC, 1999, pp. 256.
50. D.S. Young, Effects of Drugs on Clinical Laboratory Tests, (Fourth ed.), AACC Press, Washington, DC, 1995, pp. 1462.